Natera Inc. ( (NTRA) ) has released its Q4 earnings. Here is a breakdown of the information Natera Inc. presented to its investors.
Natera Inc., a leader in cell-free DNA and genetic testing, operates in the healthcare sector with a focus on oncology, women’s health, and organ health. The company aims to integrate personalized genetic testing into standard care practices to enhance health outcomes.
Natera Inc. reported a significant increase in revenues for the fourth quarter and full year of 2024, driven by strong performance in its product offerings. The company achieved a 53% rise in total revenues for the fourth quarter compared to the previous year, and a 56.7% increase for the full year, reflecting robust growth in its testing services.
Key financial metrics reveal that Natera processed approximately 792,800 tests in the fourth quarter of 2024, marking a 26.5% increase from the same period in 2023. The company also reported a notable rise in oncology tests performed, with a 54.7% increase in the fourth quarter. Natera’s gross margin improved to 62.9% in the fourth quarter, up from 51.4% in the previous year, highlighting enhanced operational efficiency.
Despite a net loss of $53.8 million for the fourth quarter, Natera’s financial position strengthened with positive cash flow of $45.7 million and an increase in cash and short-term investments to $968.3 million by year-end. The company’s strategic focus on expanding its product offerings and improving cost efficiencies contributed to a reduced net loss for the year.
Looking ahead, Natera anticipates continued revenue growth in 2025, projecting total revenues between $1.87 billion and $1.95 billion. The company remains optimistic about its future prospects, driven by ongoing innovations and potential catalysts that could further enhance its market position in the coming years.